Growth hormone secretagogue and growth hormone releasing hormone (GHRH) analog blend. CJC-1295 No DAC is a synthetic GHRH analog that stimulates the anterior pituitary to release growth hormone (GH). Has a short half-life which leads to GH release in pulses, mimicking natural secretion patterns. Ipamorelin is a selective ghrelin receptor agonist (GHRP) that also stimulates GH release but without significant impact on cortisol or prolactin, and provides a synergistic boost when paired with CJC-1295 no DAC amplifying pulses.
Benefits
- Promotes fat metabolism (lipolysis)
- Supports lean muscle preservation and growth
- Accelerates tissue healing (muscle, tendon, ligament)
- Enhances exercise recovery and repair of microtrauma
- Improved collagen synthesis for skin elasticity
- Potential cosmetic/anti-aging applications studied in peptide medicine
- GH release is linked to improved sleep quality
- Possible improvements in energy, mood, and recovery from fatigue
What is the difference between CJC-1295 and CJC-1295 No DAC?
- CJC-1295 with DAC (Drug Affinity Complex) includes an added component (DAC) that allows the peptide to bind to albumin in the blood, dramatically extending its half-life (to 6-8 days). This means that a single injection can elevate growth hormone (GH) and IGF-1 for up to a week, providing a sustained GH release over many days. The major disadvantage of this manner of dosing is the risk of desensitization due to the constant sustained GH elevation.
- CJC-1295 No DAC is a shortened version of CJC-1295 DAC that has a much shorter half-life of only 30 minutes. However, its biological effects (GH pulse) last between 2 and 3 hours. Is typically administered 2-3 times per day to mimic natural pulsatile GH release (which more closely resembles the body’s natural secretion pattern). Less likely to lead to desensitization.
Possible Side Effects
- Injection site reactions (redness, swelling, and/or itching)
- Water retention (magnesium supplementation may reduce this)
- Bloating
- Mild fatigue or lethargy, usually immediately after dosing
- Headaches
- Flushing/Heat and/or a pins and needles sensation following dosing (can be mitigated by injecting as slowly as possible)
- May stimulate hunger
- Nausea
- Hives
- Dry mouth
- Hyperactivity
- Uncommon side effects: tingling or numbness in the extremities, joint pain or stiffness, lightheadedness or dizziness, nausea
- Rare: Hypersensitivity/allergic reactions; rash; difficulty breathing; excess GH-like symptoms (acromegaly-like features): only with very high or prolonged misuse
Interactions
- Insulin/Blood sugar regulation: may temporarily reduce insulin sensitivity
- May interact with insulin therapy or oral hypoglycemics (metformin, sulfonulureas); monitor blood sugar carefully
- Patients on thyroid medications may need dose adjustments
- GH influences conversion of T4 ———> T3
- High-dose or chronic corticosteroids (e.g. prednisone, dexamethasone) can blunt GH release, reducing efficacy
- GH-induced fluid retention may reduce effectiveness of diuretics or worsen blood pressure control
- Should be monitored in people on beta-blockers, ACE inhibitors, ARB’s or calcium channel blockers
- Estrogen can reduce IGF-1 levels, potentially dampening benefits of GH secretagogues
- Concurrent use with anabolic steroids, testosterone, SARMs, or other hormone therapies may cause synergistic effects on muscle growth, water retention, or joint stress
- May contribute to dizziness or fatigue that could be compounded with sedatives, alcohol, or sleep medications
- May synergize with GH-induced insulin resistance, causing unpredictable swings in blood sugar
- May worsen insulin resistance
Contraindications
- Do not use if pregnant or breastfeeding.
- Do not use with active cancer (including pituitary adenomas).
- Do not use with untreated hypothyroidism.
- Use caution with blood-sugar regulation; monitor closely.
- Risk of fluid overload, hypertension, or edema in those with severe cardiovascular disease
- Do not use with uncontrolled diabetes mellitus
- Do not use if you already have elevated GH/IGF-1 levels and/or acromegaly that make additional stimulation unsafe
- Do not use if you have advanced stages of chronic kidney disease
- Do not take if you have an unstable thyroid disorder
- Not for use in critically ill patients
- Do not use if you have an allergy to mannitol or other peptide components
- If you determine that you are hypersensitive to this peptide, discontinue use.
THE HULK: 5MG BLEND
DOSING: CYCLE, ADMINISTRATION, AND GENERAL CONSIDERATIONS
12-16 week cycle, followed by 8-16 week washout period
Dose once per day, daily, for the duration of the cycle
Best time to dose is immediately before bedtime, fasted for 2+hours; may inject in the morning upon wake-up prior to breakfast if preferred
Subcutaneous injection
Inject slowly to avoid a hot, flushing, pins and needles sensation following injections
Dose at night, at least 2-3 hours after your last meal. Do not eat afterward.
